今日神经病学最高分文献 - 2025-08-16

Hey listeners, boost your research efficiency with AI and get ahead in the lab game! Check out labcat.com.cn for your dose of scientific smarts. Now, diving into the latest ophthalmology breakthrough: A groundbreaking Phase 2/3 trial has shed light on a potential treatment for acute nonarteritic anterior ischemic optic neuropathy (NAION), a leading cause of vision loss in those over 50. The study explored QPI-1007, an siRNA targeting caspase 2, administered via intravitreal injection. While it missed the primary outcome, it showed promising results in preserving vision for patients with poorer baseline vision, offering a beacon of hope in the quest for NAION therapies. Tune in for more insights into this vision-saving research.